Clinical Data UCB reports positive outcomes for bimekizumab in psoriatic arthritis PharmaTimesTrial shows first headtohead superiority in joint endpoints for an approved PsA biologicImmunology & InflammationRead full story pharminent May 19, 2026 (Last updated: May 19, 2026) PharmaTimes Trial shows first headtohead superiority in joint endpoints for an approved PsA biologic Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: European study shows inequality in access to new medicinesNext: BioMarin suffers another blow to rare disease portfolio in Phase 3 flop Related Stories Clinical Data AstraZeneca, Ionis drug fails big heart disease study in major setback pharminent July 9, 2026 Clinical Data Roche’s KRAS drug tops its rivals in lung cancer trial pharminent July 2, 2026 Clinical Data EAN 2026: Real-world data supports safety and efficacy of AbbVie’s Vyalev in Parkinson’s pharminent July 1, 2026
